Eris Lifesciences has announced a strategic partnership with Natco Pharma Limited for the commercialisation of semaglutide in India, marking a significant expansion of the company's diabetes and metabolic care portfolio. The collaboration follows Natco Pharma's regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market.

Regulatory Approval and Launch Timeline

Natco Pharma has successfully obtained CDSCO approval to manufacture generic semaglutide, with the product launch expected in March 2026. This regulatory milestone paves the way for introducing this advanced diabetes therapy to Indian patients through the strategic partnership.

Product Significance and Market Opportunity

Semaglutide, a GLP-1 receptor agonist, represents a transformative therapy for Type 2 diabetes management and chronic weight management. The drug has demonstrated robust clinical outcomes in glycemic control and weight reduction globally. With India experiencing a rapidly growing diabetic population and increasing awareness around obesity management, GLP-1 therapies present a high-growth opportunity within the metabolic segment.

Strategic Partnership Framework

The collaboration leverages complementary strengths from both companies. Eris brings its robust commercial infrastructure and established diabetes franchise presence, including wide specialist reach and deep engagement with endocrinologists, diabetologists, and physicians across India. Natco contributes its manufacturing capabilities and regulatory expertise in complex formulations.

Leadership Perspective

Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences, emphasized the strategic importance of this partnership, stating that semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. He highlighted the company's proactive preparation for the GLP-1 opportunity and positioned this partnership as a long-term value driver for sustained growth in the diabetes segment.

Eris Lifesciences Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing steady growth in its pharmaceutical business. The Board of Directors approved the results in their meeting held on February 13, 2026, followed by an investor presentation under Regulation 30.

Financial Performance Overview

The company delivered robust performance across key financial metrics during the third quarter of FY26. Revenue growth was driven primarily by increased product sales, while the company maintained its focus on operational efficiency.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Eris Lifesciences demonstrated consistent growth momentum. The company's consolidated revenue from operations increased to ₹2,372.86 crore from ₹2,188.34 crore in the corresponding period of the previous year.

Domestic Branded Formulations Segment

The Domestic Branded Formulations (DBF) segment showed strong performance with revenue of ₹696 crore in Q3 FY26, representing 10% year-over-year growth. The nine-month DBF revenue reached ₹2,106 crore, up 10% from the previous year.

International Business Growth

The international business segment delivered exceptional performance with Q3 revenue of ₹111 crore, marking 45% year-over-year growth. This represents the strongest quarterly performance for the segment. The nine-month international revenue stood at ₹259 crore with 11% growth.

Impact of New Labour Codes

The company recorded exceptional items of ₹17.24 crore during Q3 FY26 due to the implementation of new labour codes by the Government of India, effective November 21, 2025. These codes consolidated multiple existing labour legislations into a unified framework, resulting in increased gratuity and leave liabilities arising from changes in the definition of "wages" for employees and contract labours.

Corporate Actions and Developments

Subsequent to the quarter end, on January 16, 2026, the company completed a significant transaction involving Swiss Parenterals Limited. Eris Lifesciences allotted 23,06,372 fully paid-up equity shares at an issue price of ₹1835.35 per share through private placement, acquiring the remaining 30% stake in Swiss Parenterals Limited, making it a wholly-owned subsidiary.

Key Financial Ratios

The company maintained healthy financial ratios during the quarter, showing improved capital structure management.

The company's debt-equity ratio improved to 0.67 times from 0.79 times in the previous year, indicating better capital structure management. The interest service coverage ratio strengthened to 4.33 times, reflecting improved earnings relative to finance costs.

Analyst and Investor Call Transcript

On February 20, 2026, Eris Lifesciences informed the stock exchanges that the transcript of the analyst and investor call held after the announcement of Q3 FY26 financial results is now available on the company's website. The transcript can be accessed at the company's official website under the financials section, providing detailed insights into the quarterly performance and management commentary on business outlook.